NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » News » Company News » Genosity receives CLIA approval for AsTra Profile and AsTra Next to enable earlier detection of cancer relapse » analysis-2030261_640

Genosity receives CLIA approval for AsTra Profile and AsTra Next to enable earlier detection of cancer relapse

NS Medical Devices is using cookies

Genosity receives CLIA approval for AsTra for earlier detection of cancer relapse. (Credit: Pixabay/Konstantin Kolosov.)

Related Article

Biggest players in the global wound care market

RECOMMENDED COMPANIES

MOST READ

Scopio Labs gets FDA nod for digital bone marrow aspirate application

Viz.ai, NICO collaborate on improving intracerebral hemorrhage outcomes

Outset Medical and U.S. Renal Care partner to expand home haemodialysis in US

FDA classifies Boston Scientific’s recall of Obsidio Embolic as most serious

Xstim secures FDA approval for spine fusion stimulator

Recommended Whitepaper